We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc
ARNA

Delisted

ARNA was delisted on the 10th of March, 2022.

Back to rankings

128 hedge funds and large institutions have $160M invested in Arena Pharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 32

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

21% more call options, than puts

Call options by funds: $1.39M | Put options by funds: $1.15M

2% more funds holding

Funds holding: 125 → 128 (+3)

24% less capital invested

Capital invested by funds: $210M → $160M (-$50M)

Holders
128
Holders Change
+3
Holders Change %
+2.4%
% of All Funds
3.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
52
Reduced
32
Closed
14
Calls
$1.39M
Puts
$1.15M
Net Calls
+$245K
Net Calls Change
-$191K

Top Buyers

1
AC
Ascend Capital
California
+$2.83M
2
BFA
BlackRock Fund Advisors
California
+$1.88M
3
PAM
Panagora Asset Management
Massachusetts
+$1.21M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$1.12M
5
Morgan Stanley
Morgan Stanley
New York
+$973K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.8M
2
CCM
Camber Capital Management
Massachusetts
-$9.68M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.93M
4
GC
Globeflex Capital
California
-$1M
5
TC
TFS Capital
Pennsylvania
-$818K
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
51
VOYA Investment Management
Georgia
$160K – – –
VKH
52
Virtu KCG Holdings
New York
$149K +$163K +10,501 New
UBS Group
53
UBS Group
Switzerland
$144K +$53.9K +3,483 +53%
SG Americas Securities
54
SG Americas Securities
New York
$140K +$44.5K +2,870 +41%
D.E. Shaw & Co
55
D.E. Shaw & Co
New York
$138K +$120K +7,722 +382%
TC
56
TFS Capital
Pennsylvania
$116K -$818K -52,802 -87%
Legal & General Group
57
Legal & General Group
United Kingdom
$111K +$38.8K +2,504 +48%
HSBC Holdings
58
HSBC Holdings
United Kingdom
$103K +$64K +4,135 +134%
Tudor Investment Corp
59
Tudor Investment Corp
Connecticut
$103K +$74.6K +4,818 +200%
CCMH
60
Cornerstone Capital Management Holdings
New York
$100K -$213K -13,720 -66%
PWAG
61
Polaris Wealth Advisory Group
California
$95K +$103K +6,674 New
UBS AM
62
UBS AM
Illinois
$88K -$89.7K -5,790 -48%
Invesco
63
Invesco
Georgia
$86K +$6.1K +394 +7%
Squarepoint
64
Squarepoint
New York
$76K +$83.1K +5,362 New
Bank of America
65
Bank of America
North Carolina
$68K +$47.3K +3,051 +177%
HK
66
Horizon Kinetics
New York
$64K – – –
Principal Financial Group
67
Principal Financial Group
Iowa
$63K +$3.64K +235 +6%
Barclays
68
Barclays
United Kingdom
$61K +$15.3K +989 +31%
Creative Planning
69
Creative Planning
Kansas
$60K -$3.45K -223 -5%
LWM
70
Lyons Wealth Management
Florida
$60K – – –
AIM
71
Acrospire Investment Management
Illinois
$54K +$57K +3,680 +2,831%
Axa
72
Axa
France
$53K +$57.9K +3,740 New
TSS
73
Two Sigma Securities
New York
$50K +$29.2K +1,886 +116%
PCM
74
Prelude Capital Management
New York
$48K +$11.2K +720 +27%
Two Sigma Advisers
75
Two Sigma Advisers
New York
$47K -$1.7K -110 -3%
1 2
3
4 5

ARNA Hedge Fund Activity: Q4 2016 in Review

128 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q4 2016, worth a combined $160M — down 24% from $210M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ARNA positions and 14 closed out — a net gain of 4 holders — while 52 added to existing stakes and 32 trimmed.

The largest buyer was Ascend Capital, opening a new position worth an estimated $2.83M. The largest seller was Fidelity Investments, cutting an estimated $11.8M.

  • 128 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q4 2016, up from 125 in Q3 2016.
  • Funds reported $160M of Arena Pharmaceuticals Inc stock for Q4 2016, down 24% quarter-over-quarter.
  • 18 funds opened new Arena Pharmaceuticals Inc positions in Q4 2016 and 14 closed out, a net change of +4 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q4 2016 was Ascend Capital, an estimated $2.83M added.
  • The largest Arena Pharmaceuticals Inc seller in Q4 2016 was Fidelity Investments, an estimated $11.8M sold.

Based on aggregated 13F filings for Q4 2016.